Shares of agilon health, inc. (AGL) plunged 5.12% during Friday's intraday trading session, following a significant price target cut by Deutsche Bank. The healthcare company's stock came under pressure after the investment bank reduced its target price for Agilon Health to $1 from $2, marking a 50% decrease.

The downward revision in price target reflects growing concerns about Agilon Health's future prospects. Despite the sharp reduction, Deutsche Bank maintained its "hold" rating on the stock. This adjustment comes at a time when the average analyst rating for Agilon Health remains at "hold," with a mean price target of $4.33, according to a FactSet poll of analysts.

The stark contrast between Deutsche Bank's new $1 target and the average $4.33 target highlights the diverging views among analysts regarding Agilon Health's valuation. Investors appear to be reacting negatively to the lowered expectations, as reflected in the stock's significant drop. As the healthcare sector continues to face challenges, market participants will likely keep a close eye on further analyst updates and the company's upcoming performance metrics.